Aquapharm Biodiscovery, of Oban, Scotland, appointed Steve Harris nonexecutive chairman of the board and Sandy McDougall chief financial officer.

aTyr Pharma, of San Diego, named James Cai senior vice president of clinical development at aTyr Pharma and president of Pangu BioPharma, a fully owned aTyr Pharma subsidiary in Hong Kong.

Bioheart Inc., of Sunrise, Fla., named Michael Brown and Judy Brown research consultants.

BioMarin Pharmaceutical Inc., of Novato, Calif., named Henry J. Fuchs senior vice president and chief medical officer.

Biota Holdings Ltd., of Melbourne, Australia, appointed James Fox a nonexecutive director and chairman.

Cellerix, of Madrid, Spain, appointed Eduard Enrico Holdener to its board.

China-Biotics Inc., of Shanghai, China, named Lewis Fan chief financial officer.

CorNova Inc., of Burlington, Mass., named Andrew T. Jay to its board.

Dynavax Technologies, of Berkeley, Calif., appointed J. Tyler Martin chief medical officer.

EPIX Pharmaceuticals Inc., of Lexington, Mass., named Elkan Gamzu its CEO.

Fate Therapeutics Inc., of La Jolla, Calif., named Dan Shoemaker chief technology officer and Ken Batchelor chief scientific officer.

Genzyme Inc., of Cambridge, Mass., appointed Dominic Carolan senior vice president for the Haverhill, UK, and Waterford, Ireland, operations, and Simon Cousins vice president of contract manufacturing organizations at the Haverhill facility.

Lakewood-Amedex Inc., of Sarasota, Fla., appointed William J. Robison to its board.

MedAvante Inc., of Hamilton, N.J., named Michael Detke chief medical officer and director of the MedAvante Research Institute.

Medicilon/MPI Preclinical Research, of Shanghai, China, named Dean E. Rodwell president and chief operating officer.

Metabasis Therapeutics Inc., of San Diego, appointed Tran B. Nguyen vice president and chief financial officer.

Neugenesis Corp., of Burlingame, Calif., appointed Michael J. Buckley chief operating officer.

Ore Pharmaceuticals Inc., of Gaithersburg, Md., named Mark J. Gabrielson president and CEO.

Orexigen Therapeutics Inc., of San Diego, appointed Patrick Mahaffy to its board.

PDL BioPharma Inc., of Incline Village, Nev., elected Frederick Frank and Jody Lindell to its board.

PURE Bioscience, of San Diego, appointed John J. Carbone to its board.

Rockwell Medical Technologies Inc., of Wixom, Mich., appointed Richard Yocum vice president of drug development and medical affairs.

Savara Inc., of Austin, Texas, elected Nevan Elam, Curt Bilby and Matthew Dennis to its board.

Urigen Pharmaceuticals Inc., of San Francisco, appointed Jeffrey G. Proctor to its scientific advisory board.